Investors are suing Iovance Biotherapeutics, a biotechnology company, alleging that the company and its executives misled shareholders by making false or misleading statements about the company's business, operations, or financial prospects. The plaintiffs claim that when the truth about the company's actual situation came to light, the stock price dropped significantly, causing financial harm to investors who had purchased shares at artificially inflated prices. The proposed class includes people who bought Iovance Biotherapeutics stock during a specific period when the allegedly misleading statements were being made. The lawsuit seeks to recover losses suffered by these shareholders as a result of the defendants' alleged failure to disclose accurate and complete information to the investing public.
The case is in its earliest stage. The defendant has not yet responded. Class certification — the court's decision on whether the case can proceed as a class action — typically takes 12 to 24 months after filing.
Source: CourtListener docket entry. This summary was generated automatically and may not reflect subsequent filings.
A participating attorney may be able to evaluate your claim at no cost to you.